血友病基因治疗:预见意外情况
血友病治疗在过去60年经历多次变革,基因治疗有望为部分A型或B型血友病患者带来功能性治愈。腺相关病毒(AAV)载体经优化后可使凝血因子达到治疗水平,但许多患者不符合条件,安全性、持久性和可靠性等问题仍待解答。
要点
- AAV载体携带凝血因子VIII或IX转基因,优化后可使部分临床试验参与者达到治疗水平凝血因子。
- 表达足够蛋白的多数临床试验参与者中,突破性出血和外源性凝血因子使用几乎被消除。
- 第一代基因治疗已启动监管审评,但许多患者不符合条件,安全性、持久性和可靠性问题仍待解答。
核心结论
- 第一代基因治疗将减轻或消除许多符合条件患者的血友病负担,但许多患者不符合条件,安全性、持久性和可靠性等问题仍待解答。
研究设计与样本
- 原文为综述,回顾了过去25年血友病基因治疗的发展历程与相关临床试验结果。
主要发现
- AAV被证明是携带凝血因子VIII和IX转基因的有用载体,经盒优化和剂量递增后多个组达到治疗水平凝血因子。
- 表达足够蛋白的多数临床试验参与者中,突破性出血和外源性凝血因子使用几乎被消除。
- 第一代基因治疗已启动监管审评,将减轻或消除许多符合条件患者的血友病负担。
- 不符合条件的患者包括对多种AAV血清型血清阳性或交叉反应者、儿童、有合并症者以及基本血浆源性凝血因子不可靠可获得国家的居民。
局限性
- 许多患者不符合条件,包括对多种AAV血清型血清阳性或交叉反应者、儿童、有合并症者以及基本血浆源性凝血因子不可靠可获得国家的居民。
- 安全性、持久性和可靠性等问题仍待解答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of gene therapy to produce functional cures in some persons with hemophilia A or B. The path toward achieving subnormal to normal levels of factor VIII and factor IX activity has not been straightforward and is littered with failures over these past 25 years. Through setbacks and iteration, adeno-associated virus (AAV) proved to be a useful vector to carry the factor VIII and IX transgenes; once cassettes were optimized and dose escalation proceeded, therapeutic levels of clotting factors were achieved by several groups. Because these transgenes produce fully active proteins, breakthrough bleeding and the use of exogenous clotting factors have nearly been eliminated for most clinical trial participants when they express a sufficient amount of protein. These first-generation gene therapies, which have initiated regulatory review, will decrease or eliminate the burden of hemophilia for many of the patients who are eligible to receive them. However, many are ineligible, including those who are seropositive or cross-reactive to multiple AAV serotypes, children, those with comorbid conditions, and those who live in countries where even the most basic plasma-derived clotting factors are not reliably available. Thus, although the first-generation gene therapies will have an important impact on the burden of hemophilia, many questions remain to be answered regarding safety, durability, and reliability as this technology advance progresses toward individuals worldwide with hemophilia.
引用
- Pierce GF. Gene therapy for hemophilia: anticipating the unexpected. Blood Adv. 2020. PMID: 32780850. doi:10.1182/bloodadvances.2020002142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。